World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
57
Citations
12958
World Ranking
3607
National Ranking
1670

Andrew D. Weinberg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andrew D. Weinberg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 154 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Andrew D. Weinberg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew D. Weinberg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 57 D-Index — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Andrew D. Weinberg is affiliated with Providence Portland Medical Center in the United States. Their research primarily focuses on fields within medicine, notably immunology and microbiology, with a significant portion dedicated to oncology.

The scientist's research covers several interconnected subfields, including immunology, oncology, infectious diseases, molecular biology, and biotechnology. This interdisciplinary approach supports investigations into immune system mechanisms and therapeutic interventions.

Main topics covered in their work include:

  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Cancer immunotherapy and biomarkers
  • Immune cell function and interaction
  • SARS-CoV-2 and COVID-19 research
  • T-cell and B-cell immunology
  • Immune cells in cancer

Andrew D. Weinberg has been published in various academic venues. Frequent publication venues include:

  • Regular and Young Investigator Award Abstracts
  • The Journal of Immunology
  • Cell
  • Nature Communications
  • Journal of Clinical Investigation

Significant recent papers authored or coauthored by Weinberg include:

  • "T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants," 2023, Cell
  • "Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells," 2021, Nature Communications
  • "PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors," 2022, Journal of Clinical Investigation
  • "OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines," 2022, Frontiers in Immunology
  • "959 PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors," 2022, Regular and Young Investigator Award Abstracts

The scientist frequently collaborates with several other researchers in their domain. Frequent coauthors include:

  • Rebekka Duhen
  • Eric Tran
  • Colin Thalhofer
  • Bernard A. Fox
  • Michael Beymer

Best Publications

  • Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

    Thomas Duhen;Rebekka Duhen;Ryan Montler;Jake Moses

  • Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses

    Irene Gramaglia;Andrew D. Weinberg;Michael Lemon;Michael Croft

  • The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

    Irene Gramaglia;Amha Jember;Susanne D. Pippig;Andrew D. Weinberg

  • OX40 is a potent immune-stimulating target in late-stage cancer patients.

    Brendan D. Curti;Magdalena Kovacsovics-Bankowski;Nicholas Morris;Edwin Walker

  • Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development.

    Susan L. Swain;Linda M. Bradley;Michael Croft;Susan Tonkonogy

  • Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

    Barbara Valzasina;Cristiana Guiducci;Cristiana Guiducci;Heidrun Dislich;Heidrun Dislich;Nigel Killeen;Nigel Killeen

  • Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

    Andrew D. Weinberg;Martin Muy Rivera;Rodney Prell;Arden Morris

  • Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40

    Kazuo Sugamura;Naoto Ishii;Andrew D. Weinberg

  • Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.

    Andrew D. Weinberg;Keith W. Wegmann;Keith W. Wegmann;Castle Funatake;Ruth H. Whitham;Ruth H. Whitham

  • Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

    Joseph R. Maxwell;Andrew Weinberg;Rodney A. Prell;Anthony T. Vella

  • OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

    Daniel Hirschhorn-Cymerman;Gabrielle A. Rizzuto;Taha Merghoub;Adam D. Cohen

  • Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

    Jørgen Kjærgaard;Junta Tanaka;Julian A. Kim;Kevin Rothchild

  • T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

    Unknown

  • The role of OX40-mediated co-stimulation in T-cell activation and survival.

    William L. Redmond;Carl E. Ruby;Andrew D. Weinberg

  • OX-40: life beyond the effector T cell stage.

    Andrew D. Weinberg;Anthony T. Vella;Michael Croft

  • Science gone translational: the OX40 agonist story.

    Andrew D. Weinberg;Nicholas P. Morris;Magdalena Kovacsovics-Bankowski;Walter J. Urba

  • Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

    Carl E. Ruby;Melissa A. Yates;Melissa A. Yates;Daniel Hirschhorn-Cymerman;Peter Chlebeck

  • OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

    Michael J. Gough;Carl E. Ruby;William L. Redmond;Birat Dhungel

  • The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

    Amy E Moran;Magdalena Kovacsovics-Bankowski;Andrew D Weinberg

  • OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.

    Andrew D. Weinberg

  • Signaling through OX40 enhances antitumor immunity.

    Shawn M. Jensen;Levi D. Maston;Michael J. Gough;Carl E. Ruby

Frequent Co-Authors

Walter J. Urba
Walter J. Urba Providence Portland Medical Center
Bernard A. FoxEarle
Bernard A. FoxEarle Earle A. Chiles Research Institute
Michael J. Gough
Michael J. Gough Providence Portland Medical Center
Suyu Shu
Suyu Shu University of Michigan–Ann Arbor
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
David C. Parker
David C. Parker Oregon Health & Science University
Michael Croft
Michael Croft La Jolla Institute For Allergy & Immunology
Louis J. Picker
Louis J. Picker Oregon Health & Science University
Anthony T. Vella
Anthony T. Vella University of Connecticut Health Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in branching out from Immunology, nursing offers a practical and in-demand career path. Many turn to 12-month accelerated nursing programs online for non nurses to quickly transition into healthcare roles without prior nursing experience.

If securing admission is a concern, exploring absn programs with high acceptance rates could be a strategic choice. These programs help more students enter the nursing field with less competition, making the journey smoother.

For entry-level nursing careers, easy admission lpn programs provide a quicker route to become a Licensed Practical Nurse. These are ideal for those seeking hands-on patient care roles with shorter training periods.

For advanced practice opportunities, looking into the easiest np programs to get into can streamline the path to becoming a Nurse Practitioner. These programs combine flexibility with accessibility, allowing graduates to take on greater responsibilities in healthcare settings.

Best Scientists Citing Andrew D. Weinberg

Trending Scientists

Recently Published Articles